GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (FRA:AAJ) » Definitions » EV-to-FCF

Perspective Therapeutics (FRA:AAJ) EV-to-FCF : -32.61 (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Perspective Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Perspective Therapeutics's Enterprise Value is €704.32 Mil. Perspective Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-21.60 Mil. Therefore, Perspective Therapeutics's EV-to-FCF for today is -32.61.

The historical rank and industry rank for Perspective Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:AAJ' s EV-to-FCF Range Over the Past 10 Years
Min: -58.14   Med: -5.35   Max: 3.16
Current: -32.74

During the past 13 years, the highest EV-to-FCF of Perspective Therapeutics was 3.16. The lowest was -58.14. And the median was -5.35.

FRA:AAJ's EV-to-FCF is ranked worse than
100% of 358 companies
in the Medical Devices & Instruments industry
Industry Median: 29.28 vs FRA:AAJ: -32.74

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), Perspective Therapeutics's stock price is €1.35. Perspective Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.175. Therefore, Perspective Therapeutics's PE Ratio for today is At Loss.


Perspective Therapeutics EV-to-FCF Historical Data

The historical data trend for Perspective Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics EV-to-FCF Chart

Perspective Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.06 -9.42 -15.59 1.44 -2.81

Perspective Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.49 -6.52 -1.87 -2.81 -22.36

Competitive Comparison of Perspective Therapeutics's EV-to-FCF

For the Medical Devices subindustry, Perspective Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's EV-to-FCF falls into.



Perspective Therapeutics EV-to-FCF Calculation

Perspective Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=704.315/-21.596
=-32.61

Perspective Therapeutics's current Enterprise Value is €704.32 Mil.
Perspective Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-21.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perspective Therapeutics  (FRA:AAJ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Perspective Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.35/-0.175
=At Loss

Perspective Therapeutics's share price for today is €1.35.
Perspective Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.175.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Perspective Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Perspective Therapeutics (FRA:AAJ) Business Description

Traded in Other Exchanges
Address
350 Hills Street, Suite 106, Richland, WA, USA, 99354
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company operates two reportable business segments: Brachytherapy and Drug Operations. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.

Perspective Therapeutics (FRA:AAJ) Headlines

No Headlines